Critical Survey: Acutus Medical (NASDAQ:AFIB) vs. GBS (NYSE:GBS)

Insider and Institutional Ownership

56.9% of Acutus Medical shares are owned by institutional investors. Comparatively, 2.8% of GBS shares are owned by institutional investors. 5.2% of Acutus Medical shares are owned by insiders. Comparatively, 0.3% of GBS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Acutus Medical has a beta of -0.57, suggesting that its stock price is 157% less volatile than the S&P 500. Comparatively, GBS has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500.

Valuation and Earnings

This table compares Acutus Medical and GBS”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acutus Medical	$7.16 million	0.01	-$81.66 million	N/A	N/A
GBS	N/A	N/A	-$8.31 million	($0.56)	-3.16

GBS has lower revenue, but higher earnings than Acutus Medical.

Profitability

This table compares Acutus Medical and GBS’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acutus Medical	-272.74%	-311.64%	-11.57%
GBS	N/A	-85.64%	-54.42%

About Acutus Medical

Acutus Medical, Inc. designs, manufactures, and markets various tools for catheter-based ablation procedures to treat various arrhythmias in the United States and internationally. Its product portfolio includes novel access sheaths, transseptal crossing tools, diagnostic and mapping catheters, conventional and contact ablation catheters, and mapping and imaging consoles and accessories, as well as supporting algorithms and software programs. Acutus Medical, Inc. was incorporated in 2011 and is headquartered in Carlsbad, California.

About GBS

GBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.